In order to further verify the sensitivity and specificity of hs-TnI and QTc on the cardiotoxicity related to anti-HER2 targeted therapy in breast cancer, we selected the parameters at the end of treatment, the 12th month, for ROC curve prediction analysis. Here, ERBB2 is linked to breast carcinoma.